Despite this, our data suggest that the transcription factor NF-κB may be a promising therapeutic target as PTL, which acts directly on NF-κB and prevents it entering the nucleus, appeared to promote selective cell death of the cancer-specific CD133 population. The gene discussed is PROM1; the disease is cancer.